Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg bought 5,000 shares of Immuneering stock in a transaction on Monday, September 29th. The shares were bought at an average price of $7.18 per share, for a total transaction of $35,900.00. Following the acquisition, the director owned 141,766 shares of the company’s stock, valued at approximately $1,017,879.88. The trade was a 3.66% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Immuneering Price Performance

Shares of IMRX stock opened at $7.00 on Wednesday. The stock has a 50-day moving average of $5.54 and a 200-day moving average of $3.29. Immuneering Corporation has a one year low of $1.10 and a one year high of $10.08. The stock has a market cap of $290.99 million, a PE ratio of -3.70 and a beta of 0.43.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

Large investors have recently modified their holdings of the business. Kingsview Wealth Management LLC bought a new position in shares of Immuneering in the 2nd quarter valued at about $47,000. Jane Street Group LLC acquired a new position in Immuneering during the first quarter valued at approximately $32,000. XTX Topco Ltd bought a new position in Immuneering in the second quarter valued at approximately $90,000. Flower City Capital acquired a new position in shares of Immuneering during the 2nd quarter worth approximately $108,000. Finally, Two Sigma Investments LP raised its stake in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after purchasing an additional 10,126 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IMRX. Needham & Company LLC upped their price objective on shares of Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Oppenheimer raised their price target on Immuneering from $21.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Mizuho lifted their price objective on Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Wednesday, June 18th. Chardan Capital raised their target price on shares of Immuneering from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a report on Tuesday. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.40.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.